Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CABOTEGRAVIR Cause Staphylococcal infection? 8 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Staphylococcal infection have been filed in association with CABOTEGRAVIR (Apretude). This represents 0.1% of all adverse event reports for CABOTEGRAVIR.

8
Reports of Staphylococcal infection with CABOTEGRAVIR
0.1%
of all CABOTEGRAVIR reports
0
Deaths
5
Hospitalizations

How Dangerous Is Staphylococcal infection From CABOTEGRAVIR?

Of the 8 reports, 5 (62.5%) required hospitalization, and 1 (12.5%) were considered life-threatening.

Is Staphylococcal infection Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CABOTEGRAVIR. However, 8 reports have been filed with the FAERS database.

What Other Side Effects Does CABOTEGRAVIR Cause?

Product dose omission issue (1,121) Off label use (1,049) Injection site pain (924) Viral load increased (452) Pain (399) Virologic failure (275) Pathogen resistance (270) Pyrexia (255) Product use in unapproved therapeutic environment (234) Inappropriate schedule of product administration (228)

What Other Drugs Cause Staphylococcal infection?

ADALIMUMAB (1,727) METHOTREXATE (932) PREDNISONE (914) ETANERCEPT (850) TACROLIMUS (777) MYCOPHENOLATE MOFETIL (677) CYCLOPHOSPHAMIDE (625) RITUXIMAB (582) INFLIXIMAB (561) SECUKINUMAB (525)

Which CABOTEGRAVIR Alternatives Have Lower Staphylococcal infection Risk?

CABOTEGRAVIR vs CABOTEGRAVIR\RILPIVIRINE CABOTEGRAVIR vs CABOZANTINIB CABOTEGRAVIR vs CABOZANTINIB S-MALATE CABOTEGRAVIR vs CAFFEINE CABOTEGRAVIR vs CALASPARGASE PEGOL

Related Pages

CABOTEGRAVIR Full Profile All Staphylococcal infection Reports All Drugs Causing Staphylococcal infection CABOTEGRAVIR Demographics